leisure time -WSS

leisure time

author：hotspot 2025-09-28 23:48:36 - browse：447

The biotech company Acelyrin, which raised more than $500 million in an IPO this year, ran into its first major setback Monday as its investigational anti-inflammatory drug missed the primary goal in a pivotal clinical trial.

Acelyrin’s medicine, a subcutaneous treatment called izokibep, is meant to clear up lesions for patients with the common skin disease hidradenitis suppurativa, or HS, an inflammatory disorder that leads to abscesses and scars. But after 16 weeks of treatment, patients who received izokibep did not show significant improvements compared to those taking a placebo, failing the study’s primary endpoint.

Acelyrin’s share price fell more than 60% in after-hours trading Monday.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： J&J to buy cancer drug developer Ambrx Biopharma

hotspot

Wikipedia

WSS

Digital health: a case of mistaken identity

Chronically ill young patients struggle to find fertility info

ASCO eve: Let’s set the table for this year's meeting

Fentanyl is making it harder to start addiction treatment

H5N1 bird flu outbreak: Second human case reported, in Michigan

Feng Zhang, Grail founder join forces on new gene editing startup

entertainment

leisure time

leisure time

Duchenne breakthrough therapy leaves behind pioneering families

Eyeing GLP

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Readout Newsletter: Eli Lilly, AstraZeneca, Bristol Meyers Squibb

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Federal weight loss drug coverage is 30 years out of date

Guidelines to prevent youth baseball injuries need more muscle

New weight loss drugs work. But how can they best be used?

Moonlake's readout produced a cash windfall. Risks remain

Goldman Sachs launches $650M fund for life science investments

hotspot

Biogen joins immunology wave with $1.15 billion acquisition of HI

Why psychiatrists like me stop taking insurance

At JPM, Bristol Myers Squibb CEO tries to soothe investor nerves

H5N1 virus can be tracked in retail milk, scientists say

H5N1 virus can be tracked in retail milk, scientists say

Why psychiatrists like me stop taking insurance

hotspot

Wikipedia

hotspot

entertainment